Monopar Therapeutics Inc
General ticker "MNPR" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $828.1M
Monopar Therapeutics Inc follows the US Stock Market performance with the rate: 37.6%.
Estimated limits based on current volatility of 10.5%: low 24.17$, high 29.83$
Factors to consider:
- Current price 661.2% above estimated high
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [0.95$, 3.15$]
- 2024-12-30 to 2025-12-30 estimated range: [1.07$, 3.25$]
Financial Metrics affecting the MNPR estimates:
- Negative: Non-GAAP EPS, $ of -2.57 <= 0.10
- Negative: Operating profit margin, % of -100 <= 1.03
- Negative: Operating cash flow per share per price, % of -23.88 <= 2.35
- Negative: negative Net income
- Positive: Inventory ratio change, % of 0 <= 0
- Negative: Industry earnings per price (median), % of -26.04 <= 1.31
- Positive: Interest expense per share, $ of 0 <= 0
Short-term MNPR quotes
Long-term MNPR plot with estimates
Financial data
YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|
Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
Operating Expenses | $9.13MM | $10.54MM | $8.83MM |
Operating Income | $-9.13MM | $-10.54MM | $-8.83MM |
Non-Operating Income | $0.02MM | $0.04MM | $0.43MM |
R&D Expense | $6.49MM | $7.59MM | $5.60MM |
Income(Loss) | $-9.10MM | $-10.50MM | $-8.40MM |
Profit(Loss) | $-9.10MM | $-10.50MM | $-8.40MM |
Stockholders Equity | $18.94MM | $10.09MM | $5.59MM |
Assets | $20.52MM | $13.23MM | $7.35MM |
Operating Cash Flow | $-7.32MM | $-7.23MM | $-7.86MM |
Investing Cash Flow | $0.00MM | $-4.92MM | $4.93MM |
Financing Cash Flow | $10.88MM | $0.03MM | $2.03MM |
Earnings Per Share* | $-0.73 | $-0.83 | $-0.58 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.